Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Addus Homecare Corpo (ADUS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 433,260
  • Shares Outstanding, K 11,600
  • Annual Sales, $ 400,690 K
  • Annual Income, $ 12,020 K
  • 36-Month Beta 0.58
  • Price/Sales 1.09
  • Price/Cash Flow 18.99
  • Price/Book 2.64

Price Performance

See More
Period Period Low Period High Performance
1-Month
33.10 +10.88%
on 04/25/17
40.75 -9.94%
on 05/10/17
+3.30 (+9.88%)
since 04/24/17
3-Month
29.90 +22.74%
on 03/24/17
40.75 -9.94%
on 05/10/17
+2.80 (+8.26%)
since 02/24/17
52-Week
16.55 +121.75%
on 06/29/16
40.75 -9.94%
on 05/10/17
+16.45 (+81.23%)
since 05/24/16

Most Recent Stories

More News
Zacks.com featured highlights: Ollie's Bargain Outlet Holdings, Addus HomeCare, Luminex, Silgan Holdings and Two Harbors Investment

Zacks.com featured highlights: Ollie's Bargain Outlet Holdings, Addus HomeCare, Luminex, Silgan Holdings and Two Harbors Investment

SLGN : 62.89 (+0.53%)
LMNX : 20.23 (-0.25%)
TWO : 10.06 (-0.10%)
OLLI : 40.90 (-0.49%)
ADUS : 36.70 (-1.74%)
Use Rising P/E Tactic to Find Out 5 Winning Stocks

Cross the age-old barrier of low P/E investing, bet on these five stocks that boast a rising P/E.

SUMR : 1.78 (+0.56%)
SCHN : 19.95 (-1.24%)
REFR : 1.15 (+6.48%)
TVIA : 0.31 (unch)
ADUS : 36.70 (-1.74%)
New Strong Buy Stocks for May 17th

New Strong Buy Stocks for May 17th

AEIS : 77.64 (+0.67%)
AGNC : 20.61 (+0.39%)
AOSL : 18.69 (+0.32%)
AHGP : 28.70 (-0.66%)
ADUS : 36.70 (-1.74%)
Conatus (CNAT) Q1 Loss Narrows Y/Y, Revenues Beat Estimates

Conatus Pharmaceuticals Inc. (CNAT) reported first-quarter 2017 loss of 14 cents per share, in line with the Zacks Consensus Estimate but narrower than the year-ago figure of 35 cents.

CNAT : 5.42 (+2.26%)
PGNX : 6.86 (-0.15%)
NVS : 81.39 (+0.41%)
ADUS : 36.70 (-1.74%)
HealthSouth Corp (HLS) Looks Good: Stock Moves 8% Higher

HealthSouth Corporation (HLS) shares rose almost 8% in the last trading session.

HLS : 46.39 (-0.58%)
ADUS : 36.70 (-1.74%)
Addus HomeCare Announces First Quarter 2017 Earnings Release and Conference Call

Addus HomeCare Corporation (NASDAQ: ADUS), a provider of comprehensive home care services, announced today that it will release earnings for the first quarter ended March 31, 2017, on Monday, May 8, 2017,...

ADUS : 36.70 (-1.74%)
Orexigen Posts Wider-than-Expected Loss in Q4; Sales Up Y/Y

Orexigen Therapeutics, Inc.???s (OREX) loss of $2.67 per share in the fourth quarter of 2016, significantly wider than the both Zacks Consensus Estimate of a loss of 54 cents and the year-ago loss of $1.20....

HSKA : 100.35 (+2.34%)
OREX : 2.87 (-2.71%)
ALQA : 0.39 (unch)
ADUS : 36.70 (-1.74%)
Novo Nordisk: Positive CHMP Nod for Tresiba Label Expansion

Novo Nordisk A/S (NVO) announced that the Committee for Medicinal Products for Human Use (CHMP), has issued a positive opinion suggesting an update to the label for Tresiba (insulin degludec) to include...

HSKA : 100.35 (+2.34%)
NVO : 41.66 (+0.43%)
RTRX : 16.96 (+0.41%)
ADUS : 36.70 (-1.74%)
VIVUS to Regain Commercial Rights for Stendra from Sanofi

VIVUS, Inc. (VVUS) recently announced an agreement with Sanofi to reacquire the commercial rights to its erectile dysfunction drug, Stendrain Africa, the Middle East, Turkey and the Commonwealth of Independent...

ENDP : 12.71 (-1.32%)
VVUS : 1.08 (-3.57%)
SNY : 49.14 (+0.14%)
ADUS : 36.70 (-1.74%)
Roche's Rituxan Gets 'Breakthrough Therapy' Designation by FDA

Roche Holding AG's (RHHBY) member, Genentech announced that the FDA has granted Breakthrough Therapy Designation status to Rituxan (rituximab) for the treatment of pemphigus vulgaris.

HSKA : 100.35 (+2.34%)
RHHBY : 34.2200 (-0.23%)
RTRX : 16.96 (+0.41%)
ADUS : 36.70 (-1.74%)

Barchart Technical Opinion

The Barchart Opinion rating is a Hold. Short term, the outlook is Falling.

See More

Business Summary

ADDUS HOMECARE is a comprehensive provider of a broad range of social and medical services in the home. The company's services include personal care and assistance with activities of daily living, skilled nursing and rehabilitative therapies, and adult day care. Its consumers are individuals with special...

See More

Support & Resistance

2nd Resistance Point 38.22
1st Resistance Point 37.78
Last Price 36.70
1st Support Level 37.03
2nd Support Level 36.72

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.